CollPlant Biotechnologies (CLGN) holders buy 1,764,706 shares plus new warrants

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd received an ownership update as a Loewenbaum-led group and related entities reported a combined beneficial holding of 3,518,237 Ordinary Shares, representing 18.6% of the company’s 18,908,207 outstanding Ordinary Shares as of March 31, 2026.

On June 29, 2026, The Loewenbaum 1992 Trust entered into a Securities Purchase Agreement with CollPlant for 1,764,706 Ordinary Shares, Series A Warrants to purchase 1,764,706 shares, and Series B Warrants to purchase 3,529,412 shares, a transaction completed on July 6, 2026. Both warrant series have an exercise price of $0.34 per share and become exercisable only after shareholder approval expected on or about July 29, 2026; the Series A Warrants expire July 16, 2028 and the Series B Warrants expire July 16, 2031. The 18.6% figure includes shares potentially issuable within 60 days under existing options and warrants, but excludes shares underlying these new Warrants until they become exercisable.

Filing Explained

This Schedule 13D/A says the reporting persons may review their investment on a continuing basis but have no present plan or proposal for the other matters listed in Item 4(a)–(j), so it discloses no current action beyond the completed transaction.

Key Figures

Ordinary Shares purchased: 1,764,706 shares Series A Warrants: 1,764,706 shares at $0.34 Series B Warrants: 3,529,412 shares at $0.34 +3 more

6 metrics

Ordinary Shares purchased 1,764,706 shares Purchased by The Loewenbaum 1992 Trust under Securities Purchase Agreement dated June 29, 2026

Series A Warrants 1,764,706 shares at $0.34 Exercise price $0.34 per share; expire July 16, 2028; exercisable after shareholder approval

Series B Warrants 3,529,412 shares at $0.34 Exercise price $0.34 per share; expire July 16, 2031; exercisable after shareholder approval

Shares outstanding 18,908,207 Ordinary Shares Ordinary Shares outstanding as of March 31, 2026, used for ownership percentages

Aggregate beneficial ownership 3,518,237 Ordinary Shares Total beneficially owned by all Reporting Persons, representing 18.6% of outstanding shares

Loewenbaum 1992 Trust holding 1,934,706 Ordinary Shares Largest single position among Reporting Persons, equal to 10.2% of Ordinary Shares

Key Terms

Securities Purchase Agreement, Series A Warrants, Series B Warrants, beneficially own, +1 more

5 terms

Securities Purchase Agreement regulatory

"entered into a Securities Purchase Agreement with the Issuer for the purchase of 1,764,706"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

Series A Warrants financial

"Series A Warrants to purchase 1,764,706 Ordinary Shares (the "Series A Warrants")"

Series A warrants are financial tools that give the holder the right to buy shares of a company at a specific price within a certain period. They are often issued alongside investments to provide additional potential profit if the company's value increases. For investors, they can offer a chance to benefit from future growth without committing immediate capital to buying shares.

Series B Warrants financial

"Series B Warrants to purchase 3,529,412 Ordinary Shares (the "Series B Warrants")"

Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.

beneficially own regulatory

"Collectively, the Reporting Persons beneficially own in the aggregate 3,518,237 Ordinary Shares"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

Ordinary Shares financial

"Ordinary Shares, par value NIS 1.5 per share (Title of Class of Securities)"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/27/2026 - 04:00 PM Accepted by SEC EDGAR 07/27/2026 - 04:00 PM Learn about SEC filing dates

FAQ

What ownership stake in CollPlant Biotechnologies Ltd (CLGN) does the Loewenbaum group report?

The Reporting Persons collectively beneficially own 3,518,237 Ordinary Shares of CollPlant, representing 18.6% of the company’s outstanding Ordinary Shares. Percentages are calculated using March 31, 2026 outstanding share data and include shares issuable within 60 days under existing options and warrants.

What securities did The Loewenbaum 1992 Trust agree to purchase from CollPlant (CLGN)?

The Loewenbaum 1992 Trust agreed to purchase 1,764,706 Ordinary Shares, Series A Warrants to buy 1,764,706 shares, and Series B Warrants to buy 3,529,412 shares. This Securities Purchase Agreement was signed June 29, 2026 and the transaction closed on July 6, 2026.

What are the key terms of CollPlant (CLGN) Series A and Series B Warrants held by the Loewenbaum 1992 Trust?

Both Series A and Series B Warrants have an exercise price of $0.34 per share and become exercisable only after shareholder approval. Series A Warrants expire on July 16, 2028, while Series B Warrants expire on July 16, 2031, extending the potential investment horizon.

When do the new CollPlant (CLGN) warrants issued to The Loewenbaum 1992 Trust become exercisable?

The Series A and Series B Warrants become exercisable only after the Shareholder Approval Date, expected on or about July 29, 2026. Until that approval, Ordinary Shares underlying these Warrants are excluded from ownership percentage calculations disclosed by the Reporting Persons.

How many CollPlant Biotechnologies (CLGN) Ordinary Shares were used as the base for the ownership percentages?

Ownership percentages are calculated using 18,908,207 Ordinary Shares outstanding as of March 31, 2026. This figure comes from CollPlant’s Form F-3 filed July 9, 2026 and excludes Ordinary Shares underlying the new Warrants, which are not exercisable until shareholder approval.

Which CollPlant (CLGN) reporting person holds the largest individual position and how much do they own?

Among individual and entity filers, The Loewenbaum 1992 Trust reports the largest position with 1,934,706 Ordinary Shares, representing 10.2% of CollPlant’s Ordinary Shares. This position is separate from additional holdings by related individuals and entities disclosed in the same Schedule 13D/A amendment.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)

CollPlant Biotechnologies Ltd

(Name of Issuer)

Ordinary Shares, par value NIS 1.5 per share

(Title of Class of Securities)

19516R107

(CUSIP Number)

Lillian S. Loewenbaum
1000 Westbank Dr, Ste #2A,
Austin, TX, 78746
512-423-5857

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

06/29/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 19516R107

1

Name of reporting person

Loewenbaum Lilian S.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 186,289.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 186,289.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

186,289.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.0 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

See Item 11: Consists of (a) 25,000 shares of the Issuer's ordinary shares underlying American Depository Shares ("ADSs") held in the Lillian Shaw Loewenbaum Trust, and (b) 161,289 shares of the Issuer's ordinary shares underlying ADSs held by the Reporting Person directly.

SCHEDULE 13D

CUSIP Number(s): 19516R107

1

Name of reporting person

George Walter Loewenbaum

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,271,056.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 1,271,056.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

1,271,056.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.7 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

See Item 11: Consists of (a) 65,000 shares of the Issuer's ordinary shares underlying ADSs held by the Walter Loewenbaum Trust, (b) 235,917 ordinary shares underlying ADSs held by the Reporting Person directly, and (c) 970,139 ordinary shares underlying ADSs held by the Reporting Person in an IRA.

SCHEDULE 13D

CUSIP Number(s): 19516R107

1

Name of reporting person

Elizabeth S. Loewenbaum

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 20,688.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 20,688.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

20,688.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 19516R107

1

Name of reporting person

The Loewenbaum 1992 Trust

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,934,706.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 1,934,706.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

1,934,706.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

10.2 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 19516R107

1

Name of reporting person

The Waterproof Partnership, Ltd.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 35,500.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 35,500.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

35,500.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.2 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 19516R107

1

Name of reporting person

The Loewenbaum Residence Trust FBO Anna Loewenbaum

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 15,000.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 15,000.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

15,000.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.1 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 19516R107

1

Name of reporting person

The Elizabeth Scott Loewenbaum 1992 Trust

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 15,000.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 15,000.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

15,000.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.1 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 19516R107

1

Name of reporting person

Patrick Chalmers

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 5,100.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 5,100.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

5,100.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 19516R107

1

Name of reporting person

Reginald J. Hargrove

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 6,100.00
8	Shared Voting Power 234,688.00
9	Sole Dispositive Power 6,100.00
10	Shared Dispositive Power 234,688.00

11

Aggregate amount beneficially owned by each reporting person

240,788.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.3 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

See Item 11: Consists of (a) 20,688 shares of the Issuer's ADSs held by spouse, and (b) 214,000 held by trusts over which the reporting person is a trustee with shared voting and dispositive power.

SCHEDULE 13D

CUSIP Number(s): 19516R107

1

Name of reporting person

Nachum Shamir

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 29,298.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 29,298.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

29,298.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.2 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Dual citizen of United States and Israel

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary Shares, par value NIS 1.5 per share
(b)	Name of Issuer: CollPlant Biotechnologies Ltd
(c)	Address of Issuer's Principal Executive Offices: 4 Oppenheimer St, Weizmann Science Park, Rehovot, ISRAEL , 7670104.
Item 2.	Identity and Background
(a)	The Waterproof Partnership, Ltd., The Loewenbaum 1992 Trust, The Loewenbaum Residence Trust FBO Anna Loewenbaum and The Elizabeth Scott Loewenbaum 1992 Trust are collectively referred to as the "Reporting Entities" and each as a "Reporting Entity." George Walter Loewenbaum, Elizabeth S. Loewenbaum, Lilian S. Loewenbaum, Reginald J. Hargrove and Nachum Shamir are referred to herein as the "Individual Filers" and each, an "Individual Filer". The Individual Filers and the Reporting Entities are collectively referred to herein as the "Reporting Persons". The Waterproof Partnership, Ltd., a holding company, is a Texas limited partnership, with George Walter Loewenbaum and Lilian S. Loewenbaum serving as general partners. The Loewenbaum 1992 Trust, a holding company, is a Texas trust, with George Walter Loewenbaum and Lilian S. Loewenbaum serving as trustees. The Loewenbaum Residence Trust FBO Anna Loewenbaum, a holding company, is a Texas trust, with George Walter Loewenbaum and Lilian S. Loewenbaum serving as trustees. The Elizabeth Scott Loewenbaum 1992 Trust, a holding company, is a Texas trust, with George Walter Loewenbaum and Lilian S. Loewenbaum serving as trustees.
(b)	The address of each Reporting Person, other than Nachum Shamir, is 1000 Westbank Dr, Ste #2A, Austin, TX 78746. George Walter Loewenbaum, Elizabeth S. Loewenbaum, Lilian S. Loewenbaum and Reginald J. Hargrove are citizens of the United States and their current occupations are individual private investors. Nachum Shamir is a dual citizen of Israel and the United States and his occupation is a private investor. His address is 7900 Escala Dr, Austin TX 78735.
(c)	Refer (b) above
(d)	During the last five years, none of the Reporting Persons nor any general partner or trustee of the Reporting Entities (a) has been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors), or (b) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws.
(e)	Refer (d) above
(f)	Refer (b) above
Item 3.	Source and Amount of Funds or Other Consideration
	The information concerning the ownership of Ordinary Shares of the Reporting Persons set forth on the cover pages hereto is expressly incorporated by reference herein.
Item 4.	Purpose of Transaction
	On June 29, 2026, The Loewenbaum 1992 Trust entered into a Securities Purchase Agreement with the Issuer for the purchase of 1,764,706 Ordinary Shares, Series A Warrants to purchase 1,764,706 Ordinary Shares (the "Series A Warrants"), and Series B Warrants to purchase 3,529,412 Ordinary Shares (the "Series B Warrants" and, together with the Series A Warrants, the "Warrants"). The transaction was completed on July 6, 2026. The Series A Warrants have an exercise price of $0.34 per share, but are not exercisable until the date of shareholder approval, which is expected to be on or about July 29, 2026 (the "Shareholder Approval Date"). The Series A Warrants expire on July 16, 2028. The Series B Warrants have an exercise price of $0.34 per share, but are not exercisable until the Shareholder Approval Date. The Series B Warrants expire on July 16, 2031. The acquisitions of Ordinary Shares and Warrants by the Reporting Persons was for investment purposes. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price of and other market conditions relating to the Ordinary Shares or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations, and other factors deemed relevant, may form a plan or proposal to take any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, in which case the Reporting Persons will file an amendment to this Schedule 13D. No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein.
Item 5.	Interest in Securities of the Issuer
(a)	The information concerning the ownership of Ordinary Shares of the Reporting Persons set forth on the cover pages hereto is expressly incorporated by reference herein. To the best knowledge of the Reporting Persons, as of March 31, 2026, there were 18,908,207 Ordinary Shares outstanding (which number was set forth in the Form F-3 filed by the Issuer with the SEC on July 9, 2026). The calculations of percentages in this Schedule 13D are based on the number of shares of Ordinary Shares outstanding as of March 31, 2026. This amount excludes Ordinary Shares underlying the Warrants, as those are not exercisable until Shareholder Approval. Collectively, the Reporting Persons beneficially own in the aggregate 3,518,237 Ordinary Shares, representing 18.6% of the total outstanding Ordinary Shares (including the shares that may be issued to the Reporting Persons within 60 days upon the exercise of options and warrants, but excluding Ordinary Shares underlying the Warrants, as those are not exercisable until Shareholder Approval).
(b)	The information concerning the ownership of Ordinary Shares of the Reporting Persons set forth on the cover pages hereto is expressly incorporated by reference herein.
(c)	Not applicable.
(d)	Except as listed in Item 5(a), to the best knowledge of the Reporting Persons, no person other than the Reporting Persons has the right to receive, or the power to direct the receipt of dividends from, or the power to direct the receipt of proceeds of the sale of the shares of Common Stock beneficially owned by the Reporting Persons.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The Reporting Persons have entered into a Joint Filing Agreement, dated October 20, 2025, a copy of which is attached hereto as Exhibit 2 to this Schedule 13D and is incorporated herein by reference.
Item 7.	Material to be Filed as Exhibits.
	1. Joint Filing Agreement dated January 28, 2025 (incorporated by reference to Exhibit A to the Schedule 13G/A filed by the Reporting Persons on January 28, 2025). 2. Joint Filing Agreement dated October 20, 2025 (incorporated by reference to Exhibit 2 to the Schedule 13D/A filed by the Reporting Persons on October 20, 2025).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Loewenbaum Lilian S.

Signature:	/s/ Lillian S. Loewenbaum
Name/Title:	Lillian S. Loewenbaum
Date:	07/27/2026

George Walter Loewenbaum

Signature:	/s/ George Walter Loewenbaum
Name/Title:	George Walter Loewenbaum
Date:	07/27/2026

Elizabeth S. Loewenbaum

Signature:	/s/ Elizabeth Loewenbaum
Name/Title:	Elizabeth Loewenbaum
Date:	07/27/2026

The Loewenbaum 1992 Trust

Signature:	/s/ George Walter Loewenbaum
Name/Title:	George Walter Loewenbaum/Trustee
Date:	07/27/2026

Signature:	/s/ Lillian S. Loewenbaum
Name/Title:	Lillian S. Loewenbaum/Trustee
Date:	07/27/2026

The Waterproof Partnership, Ltd.

Signature:	/s/ George Walter Loewenbaum
Name/Title:	George Walter Loewenbaum/General Partner
Date:	07/27/2026

Signature:	/s/ Lillian S. Loewenbaum
Name/Title:	Lillian S. Loewenbaum/General Partner
Date:	07/27/2026

The Loewenbaum Residence Trust FBO Anna Loewenbaum

Signature:	/s/ George Walter Loewenbaum
Name/Title:	George Walter Loewenbaum/Trustee
Date:	07/27/2026

Signature:	/s/ Lillian S. Loewenbaum
Name/Title:	Lillian S. Loewenbaum/Trustee
Date:	07/27/2026

The Elizabeth Scott Loewenbaum 1992 Trust

Signature:	/s/ George Walter Loewenbaum
Name/Title:	George Walter Loewenbaum/Trustee
Date:	07/27/2026

Signature:	/s/ Lillian S. Loewenbaum
Name/Title:	Lillian S. Loewenbaum/Trustee
Date:	07/27/2026

Patrick Chalmers

Signature:	/s/ Patrick Chalmers
Name/Title:	Patrick Chalmers
Date:	07/27/2026

Reginald J. Hargrove

Signature:	/s/ Reginald J. Hargrove
Name/Title:	Reginald J. Hargrove
Date:	07/27/2026

Nachum Shamir

Signature:	/s/ Nachum Shamir
Name/Title:	Nachum Shamir
Date:	07/27/2026